Elicio Therapeutics Inc. is using precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. Founded in 2011, the company has developed an innovative pipeline of cancer immunotherapies addressing critical unmet needs. <br /><br />Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008.
